{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:02:21Z","timestamp":1761919341713},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hepatitis Rep"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s11901-010-0039-1","type":"journal-article","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T01:35:08Z","timestamp":1271727308000},"page":"75-90","source":"Crossref","is-referenced-by-count":28,"title":["A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B"],"prefix":"10.1007","volume":"9","author":[{"given":"Vandana","family":"Khungar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven-Huy","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"key":"39_CR1","first-page":"161","volume-title":"Hepatitis B virus","author":"JH Kao","year":"2002","unstructured":"Kao JH, Chen DS: The natural history of hepatitis B virus infection. In Hepatitis B Virus. Edited by Lai CL, Locarnini S. London: International Medical Press; 2002:161\u2013172."},{"issue":"3","key":"39_CR2","first-page":"1","volume":"50","author":"ASF Lok","year":"2009","unstructured":"\u2022\u2022 Lok ASF, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50 (3): 1\u201336. This article presents the most up-to-date American guidelines for the treatment of chronic hepatitis B; these are the national standard of care.","journal-title":"Hepatology"},{"key":"39_CR3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association for the Study of the Liver","year":"2009","unstructured":"\u2022\u2022 European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227\u2013242. This article presents the most up-to-date European guidelines for the treatment of chronic hepatitis B, which help to put the American Association for the Study of Liver Diseases guidelines into perspective.","journal-title":"J Hepatol"},{"key":"39_CR4","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"\u2022\u2022 Fontana RJ: Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185\u2013S195. This article presents the most complete narrative review on the side effects of oral antiviral therapy for hepatitis B.","journal-title":"Hepatology"},{"key":"39_CR5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","volume":"46","author":"G Birkus","year":"2002","unstructured":"Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemo 2002;46:716\u2013723.","journal-title":"Antimicrob Agents Chemo"},{"key":"39_CR6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","volume":"333","author":"R McKenzie","year":"1995","unstructured":"McKenzie R, Fried MW, Sallie R, et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analog for chronic hepatitis B. N Engl J Med 1995, 333:1099\u20131105.","journal-title":"N Engl J Med"},{"key":"39_CR7","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","volume":"50","author":"CM Lange","year":"2009","unstructured":"Lange CM, Bojunga J, Hofmann WP, et al.: Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001\u20132006.","journal-title":"Hepatology"},{"key":"39_CR8","unstructured":"Lamivudine [package insert]. Research Triangle Park, NC: Glaxo SmithKline; 2008."},{"key":"39_CR9","unstructured":"Adefovir [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2008."},{"key":"39_CR10","unstructured":"Entecavir [package insert]. Princeton, NJ: Bristol-Meyers Squibb; 2009."},{"key":"39_CR11","unstructured":"Telbivudine [package insert]. Cambridge, MA: Idenix Pharmaceuticals; 2008."},{"key":"39_CR12","unstructured":"Tenofovir [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2008."},{"key":"39_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","volume":"339","author":"CL Lai","year":"1998","unstructured":"Lai CL, Chien RN, Leung NW, et al.: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61\u201368.","journal-title":"N Engl J Med"},{"key":"39_CR14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2005.08.020","volume":"44","author":"Y Benhamou","year":"2006","unstructured":"Benhamou Y, Thibault V, Vig P, et al.: Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006, 44:62\u201367.","journal-title":"J Hepatol"},{"key":"39_CR15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology 2006, 131:1743\u20131751.","journal-title":"Gastroenterology"},{"key":"39_CR16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","volume":"13","author":"E Schiff","year":"2007","unstructured":"Schiff E, Ching-Lung L, Hadziyannis S, et al.: Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007, 13:349\u2013360.","journal-title":"Liver Transpl"},{"key":"39_CR17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","volume":"50","author":"NB Ha","year":"2009","unstructured":"Ha NB, Ha NB, Garcia RT, et al.: Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009, 50: 727\u2013734.","journal-title":"Hepatology"},{"key":"39_CR18","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","volume":"66","author":"H Izzedine","year":"2004","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V, et al.: Renal Safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004, 66: 1153\u20131158.","journal-title":"Kidney Int"},{"key":"39_CR19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hep.21189","volume":"43","author":"YS Lee","year":"2006","unstructured":"Lee YS, Dong JS, Young-Suk L, et al.: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48\u00a0weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43: 1385\u20131391.","journal-title":"Hepatology"},{"key":"39_CR20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SGL, et al.: Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750\u2013758.","journal-title":"Hepatology"},{"key":"39_CR21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hep.21225","volume":"44","author":"M Zeng","year":"2006","unstructured":"Zeng M, Mao Y, Yao G, et al.: A double-blind randomized trial of adefovir dipivoxil in chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006, 44: 108\u2013116.","journal-title":"Hepatology"},{"key":"39_CR22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"RG Gish","year":"2007","unstructured":"Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96\u00a0weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133: 1437\u20131444.","journal-title":"Gastroenterology"},{"key":"39_CR23","first-page":"705A","volume":"48","author":"SB Han","year":"2008","unstructured":"Han SB, Chang TT, Chao YC, et al.: Five years of continuous entecavir for nucleoside-na\u00efve HBeAg+ chronic hepatitis B: results from study ETV-901. Hepatology 2008, 48: 705A.","journal-title":"Hepatology"},{"key":"39_CR24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al.: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5\u00a0years of therapy. Hepatology 2009, 49: 1503\u20131514.","journal-title":"Hepatology"},{"key":"39_CR25","doi-asserted-by":"crossref","unstructured":"Tenney DJ, Pokorowski KA, Rose RE, et al.: Entecavir maintains a high genetic barrier to HBV resistance through 6\u00a0years in na\u00efve patients. Presented at Digestive Disease Week. Chicago, IL; May 30\u2013June 4, 2009.","DOI":"10.1016\/S0016-5085(09)63991-3"},{"key":"39_CR26","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1111\/j.1572-0241.2008.02086.x","volume":"103","author":"E Schiff","year":"2008","unstructured":"Schiff E, Simsek H, Lee WM, et al.: Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008, 103: 2776\u20132783.","journal-title":"Am J Gastroenterol"},{"key":"39_CR27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","volume":"129","author":"CL Lai","year":"2005","unstructured":"Lai CL, Leung N, Teo EK, et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129: 528\u2013536.","journal-title":"Gastroenterology"},{"key":"39_CR28","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576\u20132588.","journal-title":"N Engl J Med"},{"key":"39_CR29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al.: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486\u2013495.","journal-title":"Gastroenterology"},{"key":"39_CR30","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.3748\/wjg.14.3549","volume":"14","author":"XS Zhang","year":"2008","unstructured":"Zhang XS, Jin R, Zhang SB, et al.: Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008, 14: 3549\u20133553.","journal-title":"World J Gastroenterol"},{"key":"39_CR31","unstructured":"US Food and Drug Administration: Potential signals of serious risks\/new safety information identified from the adverse event reporting system (AERS) between January\u2013March 2008. Available at http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082196.htm . Accessed November 2009."},{"key":"39_CR32","doi-asserted-by":"crossref","unstructured":"Leemans WF, Janssen HLA, Niesters HGM, et al.: Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008, 15:108\u2013114.","DOI":"10.1111\/j.1365-2893.2007.00906.x"},{"key":"39_CR33","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcoate EJ, Buti M, et al.: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442\u20132455.","journal-title":"N Engl J Med"},{"key":"39_CR34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2893.2009.01084.x","volume":"16","author":"LKK Tan","year":"2009","unstructured":"Tan LKK, Gilleece Y, Mandalia S: Reduced glomerular filtration rate but sustained virologic response in HIV\/hepatitis B co-infected individuals on long-term tenofovir. Journal of Viral Hepatitis 2009, 16: 471\u2013478.","journal-title":"Journal of Viral Hepatitis"},{"key":"39_CR35","doi-asserted-by":"crossref","unstructured":"Sung JJY, Lai JK, Zeuzem S, et al.: Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008: 728\u2013735.","DOI":"10.1016\/j.jhep.2007.12.026"},{"key":"39_CR36","doi-asserted-by":"crossref","unstructured":"Hannon H, Bagnis CI, Benhamou Y, et al.: The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant, 19: 386\u2013390.","DOI":"10.1093\/ndt\/gfg505"},{"key":"39_CR37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clinthera.2008.02.012","volume":"30","author":"AM Pellicelli","year":"2008","unstructured":"Pellicelli AM, Barbaro G, Francavilla R, et al.: Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther 2008, 30:317\u2013323.","journal-title":"Clin Ther"},{"key":"39_CR38","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.22250","volume":"47","author":"MM Jonas","year":"2008","unstructured":"Jonas MM, Kelly D, Pollack K, et al.: Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18\u00a0years) with chronic hepatitis B. Hepatology 2008, 47: 1863\u20131871.","journal-title":"Hepatology"},{"key":"39_CR39","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","volume":"129","author":"TT Chang","year":"2005","unstructured":"Chang TT, Gish RG, Hadziyannis SJ, et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129: 1198\u20131209.","journal-title":"Gastroenterology"},{"key":"39_CR40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hep.22323","volume":"48","author":"M Sherman","year":"2008","unstructured":"Sherman M, Yurdaydin C, Simsek H, et al.: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96\u00a0weeks. Hepatology 2008, 48: 99\u2013108.","journal-title":"Hepatology"},{"key":"39_CR41","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1440-1746.2008.05455.x","volume":"23","author":"F Suzuki","year":"2008","unstructured":"Suzuki F, Toyoda J, Katano Y, et al.: Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol 2008, 23: 1320\u20131326.","journal-title":"J Gastroenterol Hepatol"},{"key":"39_CR42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1440-1746.2008.05593.x","volume":"24","author":"H Kobashi","year":"2009","unstructured":"Kobashi H, Takaguchi K, Ikeda H, et al.: Efficacy and safety of entecavir in nucleoside-na\u00efve, chronic hepatitis b patients: phase II clinical study in Japan. J Gastroenterol Hepatol 2009, 24: 255\u2013261.","journal-title":"J Gastroenterol Hepatol"},{"key":"39_CR43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","volume":"49","author":"N Leung","year":"2009","unstructured":"Leung N, Peng CY, Hann HW, et al.: Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009, 49: 72\u201379.","journal-title":"Hepatology"},{"key":"39_CR44","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/QAD.0b013e32830b3ab5","volume":"22","author":"MG Pessoa","year":"2008","unstructured":"Pessoa MG, Gazzard B, Huang AK, et al.: Efficacy and safety of entecavir for chronic HBV in HIV\/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008, 22: 1779\u20131787.","journal-title":"AIDS"},{"key":"39_CR45","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","volume":"130","author":"M Sherman","year":"2006","unstructured":"Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039\u20132049.","journal-title":"Gastroenterology"},{"key":"39_CR46","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","volume":"129","author":"TT Chang","year":"2005","unstructured":"Chang TT, Gish RG, Hadziyannis SJ, et al.: A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129:1198\u20131209.","journal-title":"Gastroenterology"},{"key":"39_CR47","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001\u20131010.","journal-title":"N Engl J Med"},{"key":"39_CR48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D, et al.: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1\u00a0year of a randomized, double-blind trial. Hepatology 2008, 47: 447\u2013454.","journal-title":"Hepatology"},{"key":"39_CR49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","volume":"147","author":"HLY Chan","year":"2007","unstructured":"Chan HLY, Heathcote J, Marcellin P, et al.: Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med. 2007, 147: 745\u2013754.","journal-title":"Ann Intern Med."},{"key":"39_CR50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/hep.21388","volume":"44","author":"MG Peters","year":"2006","unstructured":"Peters MG, Andersen J, Lynch P, et al.: Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006, 44: 1110\u20131116.","journal-title":"Hepatology"},{"key":"39_CR51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","volume":"44","author":"FV Bommel","year":"2006","unstructured":"Bommel FV, Zollner B, Sarrazin C, et al.: Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44:318\u2013325.","journal-title":"Hepatology"},{"key":"39_CR52","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/01.meg.0000243877.17444.5e","volume":"18","author":"SA Santos","year":"2006","unstructured":"Santos SA, Uriel AJ, Park JS, et al.: Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006, 18:1247\u20131253.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Current Hepatitis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11901-010-0039-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T22:44:39Z","timestamp":1711406679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11901-010-0039-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,21]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1007\/s11901-010-0039-1","relation":{},"ISSN":["1540-3416","1541-0706"],"issn-type":[{"value":"1540-3416","type":"print"},{"value":"1541-0706","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,21]]}}}